Home › Funds › BAKER BROS. ADVISORS LP › ACAD
BAKER BROS. ADVISORS LP position in ACAD
ACADIA PHARMACEUTICALS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 42,912,904 shares of ACAD (ACADIA PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$1.09B, representing 5.68% of its reported portfolio and ranking #5 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed ACAD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's ACAD position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in ACAD in Q3 2023 at 42,864,612 shares (US$893.3M). The position peaked in Q4 2023 at 42,864,612 shares, worth US$1.34B. Across 12 filings, BAKER BROS. ADVISORS LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 42,912,904 shares valued at US$1.09B.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 42.86M | $893.30M | New |
| Q4 2023 | 42.86M | $1.34B | Hold |
| Q1 2024 | 42.86M | $792.57M | Hold |
| Q2 2024 | 42.88M | $696.77M | Hold |
| Q3 2024 | 42.88M | $659.46M | Hold |
| Q4 2024 | 42.88M | $786.81M | Hold |
| Q1 2025 | 42.88M | $712.20M | Hold |
| Q2 2025 | 42.90M | $925.28M | Hold |
| Q3 2025 | 42.90M | $915.42M | Hold |
| Q4 2025 | 42.90M | $1.15B | Hold |
| Q1 2026 | 42.90M | $954.88M | Hold |
| Q2 2026 | 42.91M | $1.09B | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACAD and 13F data
ACAD (ACADIA PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in ACAD — the largest reported positions include RTW INVESTMENTS, LP (US$180.8M), Palo Alto Investors LP (US$72.5M), BRAIDWELL LP (US$41.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACAD
- RTW INVESTMENTS, LP 7.14M sh · $180.76M · Q2 2026
- Palo Alto Investors LP 2.86M sh · $72.46M · Q2 2026
- BRAIDWELL LP 1.65M sh · $41.65M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.44M sh · $36.39M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held ACAD?
BAKER BROS. ADVISORS LP has disclosed ACAD holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in ACAD?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 42.91M shares of ACAD (ACADIA PHARMACEUTICALS INC), valued at $1.09B, representing 5.68% of its reported portfolio and ranking #5.
Has BAKER BROS. ADVISORS LP been buying or selling ACAD?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in ACAD. The position peaked in Q4 2023 at 42.86M shares.
Which other funds hold ACAD?
Other major institutional holders of ACAD include RTW INVESTMENTS, LP, Palo Alto Investors LP, BRAIDWELL LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.